Kornimate/medical-research-clean huggingface dataset:
adjunctive oral systemic vitamin e therapy on salivary nitric oxide level in patients with erosive oral lichen planus

Conditions: Lichen Planus

Summary: oral lichen planus (olp) is a chronic inflammatory disease affecting the skin, mucous membranes,s and rarely scalp and nails. it is a t-cell-mediated autoimmune disease. traditional treatment for olp is topical steroids commonly used to treat mild to moderately symptomatic lesions. recent treatment modalities for oral lichen planus include micronutrients such as antioxidants including vitamin e that modify the immune system function. the aim of this study is to evaluate the efficacy of adjunctive oral systemic vitamin e therapy on salivary nitric oxide levels in patients with erosive oral lichen planus.


Eligibility criteria:
inclusion criteria: * patients who are clinically and histopathologically confirmed of having erosive olp according to modified who criteria. * patients with erosive olp patients who will agree to take supplied medications. * ability to complete this trial. exclusion criteria: * olp patients receiving any systemic treatment such as systemic steroids, other immunosuppressive drugs, or non-steroidal anti-inflammatory drugs on past 3 months. * pregnant and breast-feeding females. * patients suffering from systemic diseases. * patients with lesions showing any dysplastic changes in the biopsy specimen. * patients who are smoking and tobacco users in any form, will not be included. * patients with both lichenoid contact reaction and lichenoid drug reactions. * patients with cutaneous lichen planus lesions
improving resectability in pancreatic neoplasms (irene)

Conditions: Pancreatic Cancer; Stereotactic Body Radiotherapy

Summary: evaluation of clinical response in terms of resectability of patients with locally advanced pancreatic cancer treated with neoadjuvant chemotherapy plus stereotactic body radiotherapy.

aim of the study is to define the percentage of patients with down-staging and clinical response after having undergone stereotactic radiotherapy + chemotherapy with neoadjuvant intent for locally advanced pancreatic carcinoma or "borderline resectable" at the time of diagnosis. the study evaluates the response to therapy in terms of resectability, of acute and delayed treatment-related toxicity, of overall survival and progression-free survival and also assesses patient's quality of life.

Eligibility criteria:
inclusion criteria: * histological diagnosis of locally advanced pancreatic carcinoma, not upfront surgically treated (according to nccn resectability criteria), without distant metastases * nccn criteria resectability status * patient's age, performance status, possible presence of comorbidity should also be considered to decide the optimal approach (upfront surgery versus neoadjuvant treatment). * if the chemotherapy treatment induces the disease to a condition of resectability, the patient will undergo a surgical evaluation * indication for radiotherapy treatment * ecog 0-2 * obtaining informed consent * not pregnant or breastfeeding exclusion criteria: * ecog\> 2 * presence of internal diseases for which radiotherapy is contraindicated, or diseases of the connective system, or gastric or duodenal ulcer in progress or acute diverticulitis, ulcerative colitis * comorbidity which in the opinion of the referring physician may constitute a risk for participation in the study * lack of availability for clinical-instrumental follow-up * previous abdominal radiotherapy.

Keywords: pancreatic cancer stereotactic body radiotherapy resectability
efficacy of a hemostatic agent (purastat®) in reducing delayed bleeding after endoscopic submucosal dissection

Conditions: Colo-rectal Cancer

Summary: the problem of delayed bleeding after endoscopic resection is becoming important due to the growing number of indications for anti-aggregation or anticoagulant treatment for cardiovascular reasons in the aging populations. previous studies have shown that in patients at high risk of bleeding, the use of (purastat®), a simple and easily applicable solution, decreases the rate of delayed bleeding by promoting wound healing. various preventive treatments, such as the prophylactic use of clips, have been tried to prevent the occurrence of delayed bleeding, but to date, no treatment has clearly shown its effectiveness. in addition, preventive hemostasis with clips is difficult and costly. the main objective is to compare the efficacy of purastat® to the standard treatment in reducing delayed bleeding after colorectal esd in patients at high risk of delayed bleeding. the secondary objectives are to compare the same two strategies in terms of effectiveness and side effects. the primary outcome measure is the percentage of delayed bleeding at 30 days after surgery (esd).


Eligibility criteria:
inclusion criteria: * patients of both sexes aged 18 years or older * patient with a validated indication for colonoscopy for colorectal lesions * patients with a single colorectal lesion to be resected by esd according to european recommendations. * patients with a colorectal neoplastic lesion (≥3 cm) * patients taking anticoagulants (acetylsalicylic acid \>300 mg/day) or antiplatelet agents (clopidogrel, prasugrel, ticagrelor, clopidogrel) and managed according to european recommendations for esd (including patients who may require heparin replacement) * written consent signed after clear, fair, and understood information. * patients with social security coverage. exclusion criteria: * patients who may have an allergic reaction to the substances of purastat®. * patients with severe fibrosis * patients with a history of familial colorectal polyposis (familial adenomatous, lynch syndrome, peutz-jeghers syndrome) * patients with a score asa greater than or equal to 4 or 5 * patients with a platelet count of 50,000/mm3 * patients with acquired (non-medicated) or inherited bleeding disorders * patients who are being treated with acetylsalicylic acid but whose treatment is discontinued at the time of the procedure (therapeutic window) * patients with advanced cancer or inflammatory bowel disease, including ulcerative colitis (with colonic involvement) * contraindication to general anesthesia * patients with a mental disorder, drug addiction, alcoholism, etc. * pregnant women or women wishing to become pregnant during the study * patients already participating or scheduled to participate in other clinical trials * lesion that has been previously resected by mucosectomy * patient with an initial metastatic lesion prior to colonoscopy. * patient unable to give personal consent * lack of signed informed consent

Keywords: resection colorectal lesions bleeding esd
a study comparing vicodin® cr and norco® to placebo in subjects with acute pain following bunionectomy

Conditions: Pain

Summary: the purpose of this study is to evaluate the effectiveness (level of pain control) and safety of the administration of extended release hydrocodone/acetaminophen and immediate release hydrocodone/acetaminophen with placebo over a 12 hour dosing period in patients who have had a bunionectomy, and to assess the safety of the drug for 7 days after patients are discharged from the hospital.


Eligibility criteria:
inclusion criteria: * males and females ages 18 to 65 * scheduled to undergo primary, unilateral, first metatarsal osteotomy (bunionectomy) * must meet specific pain intensity criteria on the morning after surgery * willing to remain at the study center 2 days following surgery * if female, must be of non-child bearing potential or practicing birth control exclusion criteria: * is allergic to or has a serious reaction to hydrocodone, hydromorphone, oxycodone, acetaminophen, ketorolac, lidocaine, bupivacaine, or mepivacaine * is allergic to or has a serious reaction to aspirin or other non-steroidal anti-inflammatory drugs (nsaids) * has a history of or currently has any active seizure disorder * has a history of or any disease causing severe gastrointestinal narrowing or slowing down the gastrointestinal tract * has been diagnosed with cancer within the past 3 years * requires treatment with certain drugs for depression or psychiatric disorders * has specific clinically significant illnesses or laboratory abnormalities * received corticosteroid treatment or any investigational drug within a specific timeframe.

Keywords: acute pain following bunionectomy
dose-ranging study of spl7013 gel for the prevention of bacterial vaginosis (bv)

Conditions: Recurrent Bacterial Vaginosis (BV)

Summary: the purpose in this clinical study is to determine the efficacy of spl7013 gel for the prevention of recurrence of bacterial vaginosis.


Eligibility criteria:
inclusion criteria: * women aged 18-45 years with a history of recurrent bv, defined as at least 3 documented episodes in the previous 12 months (including the current episode). * current episode of bv as defined by subject-reported symptoms and amsel's criteria * otherwise healthy exclusion criteria: * no active stis and/or current uti * previous exposure to spl7013 gel * a papanicolaou (pap) smear result considered to be clinically significant (ie, high grade cervical intraepithelial squamous lesions \[hsil\] on cytology or cervical intraepithelial neoplasia \[cin\] grades of cin2 or cin3 on histology) in the previous 2 years or in accordance with local treatment guidelines.

Keywords: bv bacterial vaginosis recurrent spl7013 gel vivagel
the efficacy of instrument-assisted soft tissue mobilization at lumbar region disc herniations

Conditions: Lumbar Disc Herniation; Instrument-assisted Soft Tissue Mobilization

Summary: this study was carried out to investigate the effect of instrument-assisted soft tissue mobilization in patients with lomber region disc herniation. 60 patients with lumbar disc herniation between the ages of 30-65 were included in the study. following the evaluation, the patients were divided into two groups by closed envelope method; control group (n=30) and experimental group (n=30). in both groups, 4 weeks (20 sessions) hot pack (hotpack), conventional transcutaneous electrical nerve stimulation (tens), therapeutic physical therapy program with therapeutic ultrasound applications were performed. in addition to this program, instrumental assisted soft tissue mobilization (iastm) was applied to the experimental group in 12 sessions of 3 times a week. this technique was performed by using stainless steel tools of different sizes and shapes. iastm treatment was performed (including sweep-fan-brush-sweep technique, 45° angle with the skin, by 8-10 repetitions) for the ilicostalis lumborum, priformis, gluteus medius, erector spines, quadratus lumborum muscles, superficial and deep fascia. depression levels of the patients were evaluated with beck depression scale, before the treatment and after 4 weeks pain severity, vas pain scale, functional status with oswestry scale, quality of life with short form-36 (sf- 36) and normal range of motion with goniometer. the results were analyzed by using spss v.20 program. in all analyzes, the significance ratio was accepted as p \<0.05. at the end of the four-week treatment program, significant improvements were observed in vas levels, normal joint movements (flexion, extension, right-left lateral flexion, rotation) in both groups (p \<0.05). oswestry and beck depression scale scores showed significant improvement merely in the experimental group compared to the control group (p \<0.05). there was no significant difference in vas values, normal joint motion and oswestry scale while there was no notable difference in sf-36 and beck depression scale. as a result of the study, it was concluded that iastm is a more effective method on normal range of motion and functionality in comparison with traditional physiotherapy program in patients with lumbar disc herniation and it can be used as an alternative method in patients during the physiotherapy and rehabilitation program if needed.


Eligibility criteria:
inclusion criteria: 1. bulging and protruding disc presence 2. facet joint problem 3. mechanical low back pain exclusion criteria: 1. extruded and sequestrated disc presence 2. previous operational status through the lumbar region 3. having inflammatory pain (osteoarthritis) 4. pain associated with malignancy (primary or metastatic tumors) 5. severe psychological discomfort 6. having communication problems

Keywords: pain instrument-assisted soft tissue mobilization depression functionality lumbar disc herniation quality of life
psychomotor performance of preterm infants

Conditions: Psychomotor Development Impaired

Summary: the first part involved 120 children in grades ii and iii of elementary schools. from this group, children were qualified for the second part of the study - 35 randomly selected children born on time (bot) and 35 children born before 35 weeks of pregnancy (pb). eurofit tests, vienna tests and postural stability tests were carried out in both groups.


Eligibility criteria:
inclusion criteria: * preterm born (pb): born before 35 weeks of gestation * both groups: aged 7-9 y during the research project exclusion criteria: * musculoskeletal injuries * neurological disorders or other cns damage

Keywords: preterm birth preterm infant motor abilities eurofit vienna test postural stability
the prevalence of oral habits in a group of primary school children in cairo governorate

Conditions: Oral Habit

Summary: this study is designed to determine the prevalence of oral habits among primary egyptian school children in cairo governorate, egypt.

this aim of this study is to determine the prevalence of oral habits among primary egyptian school children in cairo governorate, egypt. pico: p: egyptian primary school children of 7 - 10 years old o: prevalence of oral habits primary outcome: prevalence of oral habit; device of measurement: questionnaire; unit of measurement: binary.

Eligibility criteria:
inclusion criteria: * cooperative children of 7-10 years old * children with no intellectual problems exclusion criteria: * children with orthodontic appliances * medically compromised children * children of families who refuse to participate in the study
preoperative intravenous fluid type and postoperative nausea

Conditions: Post Operative Pain; Nausea and Vomiting, Postoperative; Anxiety

Summary: in this study, it was aimed to investigate the relationship between postoperative nausea and vomiting, anxiety levels and pain scores in the postoperative period according to dosing and choosing of intravenous fluid type that the patients received in the preoperative period.

fluid management is an integral and important part of perioperative treatment. in order to prevent organ damage, a key components of assuring adequate organ perfusion is to provide adequate volume and appropriate fluid. types of the fluids, amount of the fluid given and timing of the administration are the main topics that determine the fluid management strategy. colloids (e.g. albumin or fresh frozen plasma (ffp)) and crystalloids (e.g. ringer lactate, isotonic, 5% dextrose) are types of intravenous fluids that are used for fluid replacement apart from blood transfusion . crystalloids are low-cost salt solutions with small molecules, which can move around easily when injected into the body. there are studies reporting that fluid therapy applied in the preoperative period reduces gastric acid secretion and reduces stomach movements and nausea and vomiting. in addition, there are studies reporting that fluids given in the preoperative period have a positive effect on anxiety levels by reducing the feeling of hunger and thirst in patients. there are studies reporting that fluid therapy reduces atp destruction and oxidative stress, which contributes to the reduction of pain levels. 90 asa i-ii patients who will undergo laparoscopic cholecystectomy surgery will be included in the study and will be divided into three equal groups. patients in group 1 were administered 400 ml 0.9% saline infusion within 30 minutes, 2 hours before surgery. patients in group 2 were infused with 400 ml 5% dextrose at the same infusion rate. in groups 1 and 2, 10 ml/kg/h 0.9% saline infusion was applied during the intraoperative period. patients in group 3 were administered 200 ml dextrose infusion in the preoperative period and 200 ml dextrose infusion in the intraoperative period. 0.9% saline infusion was applied so that the total intraoperative fluid volume was the same as in the other groups. postoperative nausea and vomiting (ponv) , within 24 hours was compared between groups by ponv score. other outcomes were the antiemetic drugs needed, the nrs score, the state-trait anxiety inventory , additional analgesic drug requirement. in this study, it was aimed to investigate the relationship between postoperative nausea and vomiting, anxiety levels and pain scores in the postoperative period according to dosing and choosing of intravenous fluid type that the patients received in the preoperative period.

Eligibility criteria:
inclusion criteria: * patients who underwent laparoscopic cholecystectomy * patients over the age of 18 exclusion criteria: * patients who do not accept the study * diabetes mellitus

Keywords: preoperative intravenous fluid type laparoscopic cholecystectomy
the evicel® gastrointestinal study

Conditions: Gastrointestinal Diseases

Summary: the purpose of this study is to evaluate the safety and effectiveness of evicel® fibrin sealant (human) for use as an adjunct to gastrointestinal (gi) surgery.

this is a single blind, randomized, multi-center controlled study evaluating the safety and effectiveness of evicel® when used as an adjunct to gastrointestinal (gi) surgery.

Eligibility criteria:
inclusion criteria: * subjects undergoing primary elective gi surgery * subjects ≥ 18 years of age who are willing to participate in the study and provide written informed consent prior to any study-related procedures exclusion criteria: * avastin use within 30 days prior to surgery; * known hypersensitivity to the human blood products or the components of the investigational product; * female subjects who are pregnant or nursing; * exposure to another investigational drug or device in a clinical trial within 30 days prior to surgery or planned/intended for the 90 day follow up period after surgery.
improved sensitivity detection of serum hbsag and hbsag reversion

Conditions: Hepatitis B, Chronic

Summary: the goal of this observational study is to learn about the hbsag reversion rate at 48 weeks off treatment in hbsag-negative patients by hbsag next assay which has improved sensitivity compared to current architect hbsag assay. the main question it aims to answer is: what's the hbsag reversion rate at 48 weeks off treatment in hbsag-negative patients by hbsag next assay? hbsag next assay technology (lower limit of detection for hbsag is 0.005 iu/ml) and current architect hbsag assay (lower limit of detection for hbsag is 0.05 iu/ml) are applied for hbsag detection in patients achieving functional cure, and to compare the difference in hbsag reversion rate 48 weeks off treatment under the two types of criteria.

in this study, chronic hepatitis b patients who achieved hbsag loss by current architect hbsag testing (lower limit of detection for hbsag is 0.05 iu/ml) under interferon therapy and received consolidation therapy for 3 month after that were screened for eligibility. those who are willing to discontinue were enrolled in the study. patients were divided in two groups according to hbsag levels，one with patients who were hbsag-negative （hbsag\<0.005 iu/ml）by hbsag next assay , and the other with patients who had hbsag levels between 0.005 iu/ml and 0.05iu/ml. patients were followed up for 48 weeks after discontinuation after hbsag loss and hbsag reversion rates in the two groups were analyzed and compared.

Eligibility criteria:
inclusion criteria: * hbsag-negative by abbott's hbsag test and hbeag-negative; * having serum specimens retained at baseline and at 48 weeks off treatment follow up; * being willing to follow up regularly for 1 year. exclusion criteria: * patients with hepatitis b cirrhosis in the compensated and decompensated stages: this includes patients with a clear history of cirrhosis (imaging or histological evidence) or child-pugh score ≥5 prior to nuc treatment, or who have had complications of the decompensated stage of cirrhosis, such as ascites, hepatic encephalopathy, or ruptured oesophago-gastric fundal varices bleeding; * combined hav, hcv, hdv, hev, hiv infections, alcoholic liver disease, inherited metabolic liver disease, pharmacological liver disease, non-alcoholic fatty liver disease, autoimmune liver disease and other chronic liver diseases; * primary hepatocellular carcinoma or those with afp greater than 100 ng/ml at screening and imaging suggestive of possible malignant hepatic occupancy; or patients with afp greater than 100 ng/ml for a sustained period of 3 months; * patients with a combination of other malignant tumours (excluding those who have been cured); * patients with severe diseases or uncontrolled disease * those who are also participating in other clinical studies; * patients deemed unsuitable by the investigator to participate in this study.

Keywords: hbsag next assay functional cure hbsag loss hbsag reversion
prevalence of and risk factors of obesity in school children and adolescents in nag hammadi city. 300 participants.

Conditions: Obesity, Adolescent

Summary: searching for obese children who's body mass index is above normal range and risk factors in children and adolescents in nag hammadi city


Eligibility criteria:
inclusion criteria: * children and adolescents 12to18years. exclusion criteria: * children younger than12 years and who have special conditions as deaf.

Keywords: body mass index